Harpoon Therapeutics - HARP Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HARP shares.
View HARP analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued 1-year price targets for Harpoon Therapeutics' shares. Their HARP share price forecasts range from $6.00 to $18.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 930.8% from the stock's current price.
View analysts price targets for HARP or view top-rated stocks among Wall Street analysts.

Harpoon Therapeutics' stock was trading at $7.55 at the start of the year. Since then, HARP stock has decreased by 87.2% and is now trading at $0.9701.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our HARP earnings forecast.

Harpoon Therapeutics, Inc. (NASDAQ:HARP) posted its quarterly earnings results on Wednesday, August, 10th. The company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02. The company earned $8.30 million during the quarter, compared to the consensus estimate of $9.22 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 149.52% and a negative net margin of 329.76%.

5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HARP stock can currently be purchased for approximately $0.97.

Harpoon Therapeutics (NASDAQ:HARP) has a market capitalization of $32.12 million and generates $23.65 million in revenue each year. The company earns $-116,720,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.harpoontx.com. The company can be reached via phone at (650) 443-7400 or via email at ir@harpoontx.com.